| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $142.8M | +17.7% |
| SG&A Expense | $28.2M | -1.8% |
| Operating Income | -$171.0M | -14.0% |
| Net Income | -$168.1M | -12.6% |
| EPS (Basic) | -$3.23 | -10.2% |
| EPS (Diluted) | -$3.23 | -10.2% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $172.1M | -14.3% |
| Current Assets | $265.6M | -30.5% |
| Total Assets | $306.3M | -28.0% |
| Current Liabilities | $28.1M | -2.2% |
| Total Liabilities | $54.0M | -6.1% |
| Stockholders' Equity | $252.4M | -31.5% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$153.6M | -28.5% |
| Capital Expenditures | $3.1M | -15.2% |
| Investing Cash Flow | $87.2M | +163.2% |
| Financing Cash Flow | $37.4M | -76.3% |
| Free Cash Flow | -$156.7M | -27.2% |